{"DataElement":{"publicId":"7419755","version":"1","preferredName":"Subject Characteristics Domain Clinical Trial Protocol Children's Oncology Group Stratification Factors Text","preferredDefinition":"The protocol stratum to which a patient has been assigned.","longName":"SC_SCORRES_STRTM","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7419725","version":"1","preferredName":"Subject Characteristics Domain Clinical Trial Protocol Children's Oncology Group Stratification Factors","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject characteristics._A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the ICH GCP Guideline the term protocol refers to protocol and protocol amendments. NOTE: Present usage can refer to any of three distinct entities: 1) the plan (i.e., content) of a protocol, 2) the protocol document, and 3) a series of tests or treatments (as in oncology). [ICH E6 Glossary]_An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers._Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","longName":"6408455v1.0:7419723v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6408455","version":"1","preferredName":"Subject Characteristics Domain","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject characteristics.","longName":"C49610","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subject Characteristics Domain","conceptCode":"C49610","definition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"73FAC631-EDAD-6277-E053-F662850A700F","latestVersionIndicator":"Yes","beginDate":"2018-08-21","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-08-21","modifiedBy":"ONEDATA","dateModified":"2018-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7419723","version":"1","preferredName":"Clinical Trial Protocol Children's Oncology Group Stratification Factors","preferredDefinition":"A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the ICH GCP Guideline the term protocol refers to protocol and protocol amendments. NOTE: Present usage can refer to any of three distinct entities: 1) the plan (i.e., content) of a protocol, 2) the protocol document, and 3) a series of tests or treatments (as in oncology). [ICH E6 Glossary]:An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.:Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","longName":"C142451:C39353:C16153","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Trial Protocol","conceptCode":"C142451","definition":"A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the ICH GCP Guideline the term protocol refers to protocol and protocol amendments. NOTE: Present usage can refer to any of three distinct entities: 1) the plan (i.e., content) of a protocol, 2) the protocol document, and 3) a series of tests or treatments (as in oncology). [ICH E6 Glossary]","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Children's Oncology Group","conceptCode":"C39353","definition":"An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stratification Factors","conceptCode":"C16153","definition":"Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF475DC9-1AA9-1CDA-E053-4EBD850AF9EE","latestVersionIndicator":"Yes","beginDate":"2020-09-14","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008528","version":"1","preferredName":"Protocol Administration","preferredDefinition":"the management of a research protocol and its case report forms.","longName":"PROT_ADM","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECAD41-A932-34B1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF475DC9-1ABA-1CDA-E053-4EBD850AF9EE","latestVersionIndicator":"Yes","beginDate":"2020-09-14","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"SPRINGERL","dateModified":"2020-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7419731","version":"1","preferredName":"Children's Oncology Group Stratification Factors Text","preferredDefinition":"An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers._Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol._The words of something written.","longName":"7419731v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"160","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"All Patients","valueDescription":"All Patients","ValueMeaning":{"publicId":"3192579","version":"1","preferredName":"All Patients","longName":"3192579","preferredDefinition":"All Patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C907B56-CA4F-5D16-E040-BB89AD435C2A","latestVersionIndicator":"Yes","beginDate":"2011-02-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-6245-17B6-E053-4EBD850A2842","beginDate":"2013-02-20","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"Newly Diagnosed","valueDescription":"Newly Diagnosed","ValueMeaning":{"publicId":"2578430","version":"1","preferredName":"Newly Diagnosed","longName":"2578430","preferredDefinition":"Very recently determined.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Newly Diagnosed","conceptCode":"C25587","definition":"Very recently determined.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FF6B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-30","modifiedBy":"ONEDATA","dateModified":"2006-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-6701-17B6-E053-4EBD850A2842","beginDate":"2019-06-11","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"Refractory","valueDescription":"Refractory","ValueMeaning":{"publicId":"2566882","version":"1","preferredName":"Refractory","longName":"2566882","preferredDefinition":"Not responding to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory","conceptCode":"C38014","definition":"Not responding to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D24F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-22","endDate":null,"createdBy":"PWEST","dateCreated":"2003-08-22","modifiedBy":"SOKKERL","dateModified":"2023-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-670B-17B6-E053-4EBD850A2842","beginDate":"2019-06-11","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"Relapsed","valueDescription":"Relapse","ValueMeaning":{"publicId":"2857244","version":"1","preferredName":"Relapse","longName":"2857244","preferredDefinition":"The return of signs and symptoms of cancer after a period of improvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapse","conceptCode":"C18265","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66219F23-0990-8382-E040-BB89AD432D5C","latestVersionIndicator":"Yes","beginDate":"2009-03-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-03-27","modifiedBy":"KUMMEROA","dateModified":"2023-11-17","changeDescription":null,"administrativeNotes":"2023.3.9 Added Alt VM per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-6715-17B6-E053-4EBD850A2842","beginDate":"2019-06-11","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"SR-AVG EOI HTS Undetect","valueDescription":"SR-AVG EOI HTS Undetect","ValueMeaning":{"publicId":"6691113","version":"1","preferredName":"SR-AVG EOI HTS Undetect","longName":"6691113","preferredDefinition":"SR-AVG EOI HTS Undetect","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"865A672F-70B1-5D32-E053-F662850A8192","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-6729-17B6-E053-4EBD850A2842","beginDate":"2019-04-12","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"SR-AVG HTS Det/Indet/Unav","valueDescription":"SR-AVG HTS Det/Indet/Unav","ValueMeaning":{"publicId":"6691112","version":"1","preferredName":"SR-AVG HTS Det/Indet/Unav","longName":"6691112","preferredDefinition":"SR-AVG HTS Det/Indet/Unav","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"865A672F-708E-5D32-E053-F662850A8192","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-6733-17B6-E053-4EBD850A2842","beginDate":"2019-04-12","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"SR-HIGH B-ALL","valueDescription":"SR-HIGH B-ALL","ValueMeaning":{"publicId":"6691107","version":"1","preferredName":"SR-HIGH B-ALL","longName":"6691107","preferredDefinition":"SR-HIGH B-ALL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"865A672F-6FDF-5D32-E053-F662850A8192","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-6747-17B6-E053-4EBD850A2842","beginDate":"2019-04-12","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"Stratum 1: All Patients","valueDescription":"Stratum 1: All Patients","ValueMeaning":{"publicId":"4514591","version":"1","preferredName":"Stratum 1: All Patients","longName":"4514591","preferredDefinition":"Stratum 1: All Patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04D91583-CCB0-CE64-E050-BB89AD43335F","latestVersionIndicator":"Yes","beginDate":"2014-10-07","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-676F-17B6-E053-4EBD850A2842","beginDate":"2014-10-07","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"Stratum 2","valueDescription":"Stratum 2","ValueMeaning":{"publicId":"5697685","version":"1","preferredName":"Stratum 2","longName":"5697685","preferredDefinition":"Stratum 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A1515F8-01CB-5A06-E053-F662850AF427","latestVersionIndicator":"Yes","beginDate":"2017-03-06","endDate":null,"createdBy":"RICHARDS","dateCreated":"2017-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-6779-17B6-E053-4EBD850A2842","beginDate":"2019-12-11","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"Stratum 3","valueDescription":"Stratum 3","ValueMeaning":{"publicId":"5697684","version":"1","preferredName":"Stratum 3","longName":"5697684","preferredDefinition":"Stratum 3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A1515F8-01A8-5A06-E053-F662850AF427","latestVersionIndicator":"Yes","beginDate":"2017-03-06","endDate":null,"createdBy":"RICHARDS","dateCreated":"2017-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-67A1-17B6-E053-4EBD850A2842","beginDate":"2019-12-11","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"Stratum 4 Newly Diagnosed","valueDescription":"Stratum 4 Newly Diagnosed","ValueMeaning":{"publicId":"6644368","version":"1","preferredName":"Stratum 4 Newly Diagnosed","longName":"6644368","preferredDefinition":"Stratum 4 Newly Diagnosed","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"81F150BA-3399-4002-E053-F662850ABE4C","latestVersionIndicator":"Yes","beginDate":"2019-02-15","endDate":null,"createdBy":"GALITG","dateCreated":"2019-02-15","modifiedBy":"ONEDATA","dateModified":"2019-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-67BF-17B6-E053-4EBD850A2842","beginDate":"2019-02-15","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"Stratum 5 Relapsed","valueDescription":"Stratum 5 Relapsed","ValueMeaning":{"publicId":"6644367","version":"1","preferredName":"Stratum 5 Relapsed","longName":"6644367","preferredDefinition":"Stratum 5 Relapsed","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"81F150BA-3376-4002-E053-F662850ABE4C","latestVersionIndicator":"Yes","beginDate":"2019-02-15","endDate":null,"createdBy":"GALITG","dateCreated":"2019-02-15","modifiedBy":"ONEDATA","dateModified":"2019-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-67C9-17B6-E053-4EBD850A2842","beginDate":"2019-02-15","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"Stratum 5: All patients","valueDescription":"Stratum 5: All patients","ValueMeaning":{"publicId":"6936977","version":"1","preferredName":"Stratum 5: All patients","longName":"6936977","preferredDefinition":"Stratum 5: All patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"92B2ECF6-812B-4F6A-E053-F662850AA2EA","latestVersionIndicator":"Yes","beginDate":"2019-09-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-09-16","modifiedBy":"ONEDATA","dateModified":"2019-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-67D3-17B6-E053-4EBD850A2842","beginDate":"2019-09-16","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"Stratum 6 Refractory","valueDescription":"Stratum 6 Refractory","ValueMeaning":{"publicId":"6644366","version":"1","preferredName":"Stratum 6 Refractory","longName":"6644366","preferredDefinition":"Stratum 6 Refractory","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"81F150BA-3353-4002-E053-F662850ABE4C","latestVersionIndicator":"Yes","beginDate":"2019-02-15","endDate":null,"createdBy":"GALITG","dateCreated":"2019-02-15","modifiedBy":"ONEDATA","dateModified":"2019-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-67DD-17B6-E053-4EBD850A2842","beginDate":"2019-02-15","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"Stratum 7 Newly Diagnosed Complete Response","valueDescription":"Stratum 7: Newly Diagnosed CR","ValueMeaning":{"publicId":"6659281","version":"1","preferredName":"Stratum 7: Newly Diagnosed CR","longName":"6659281","preferredDefinition":"Stratum 7: Newly Diagnosed CR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8284F7CC-FD5F-4450-E053-F662850A8E41","latestVersionIndicator":"Yes","beginDate":"2019-02-22","endDate":null,"createdBy":"GALITG","dateCreated":"2019-02-22","modifiedBy":"ONEDATA","dateModified":"2019-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-67E7-17B6-E053-4EBD850A2842","beginDate":"2019-02-27","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"Stratum 90: Screening","valueDescription":"Stratum 90: Screening","ValueMeaning":{"publicId":"7470355","version":"1","preferredName":"Stratum 90: Screening","longName":"7470355","preferredDefinition":"Stratum 90: Screening","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B20D3790-760A-3FC5-E053-4EBD850AB9A8","latestVersionIndicator":"Yes","beginDate":"2020-10-19","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-19","modifiedBy":"ONEDATA","dateModified":"2020-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B20D3790-7623-3FC5-E053-4EBD850AB9A8","beginDate":"2020-10-19","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-19","modifiedBy":"ONEDATA","dateModified":"2020-10-19","deletedIndicator":"No"},{"value":"ACNS1931 Stratum 1","valueDescription":"Stratum 1: Feasibility Patients","ValueMeaning":{"publicId":"7296923","version":"1","preferredName":"Stratum 1: Feasibility Patients","longName":"7296923","preferredDefinition":"ACNS1931 Stratum 1: Feasibility Patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A668D701-26E1-5E80-E053-4EBD850ABC27","latestVersionIndicator":"Yes","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-05-24","modifiedBy":"ONEDATA","dateModified":"2020-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-5F93-17B6-E053-4EBD850A2842","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"ACNS1931 Stratum 10","valueDescription":"Stratum 10: Efficacy Phase: indeterminate BRAF, prior Vinblastine no prior MEK","ValueMeaning":{"publicId":"7296930","version":"1","preferredName":"Stratum 10: Efficacy Phase: indeterminate BRAF, prior Vinblastine no prior MEK","longName":"7296930","preferredDefinition":"ACNS1931 Stratum 10: Efficacy Phase: indeterminate BRAF, prior Vinblastine no prior MEK","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6690ED4-85AC-7106-E053-4EBD850AFB1A","latestVersionIndicator":"Yes","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-05-24","modifiedBy":"ONEDATA","dateModified":"2020-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-5F9D-17B6-E053-4EBD850A2842","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"ACNS1931 Stratum 11","valueDescription":"Stratum 11: Efficacy Phase: indeterminate BRAF, no prior Vinblastine prior MEK","ValueMeaning":{"publicId":"7296929","version":"1","preferredName":"Stratum 11: Efficacy Phase: indeterminate BRAF, no prior Vinblastine prior MEK","longName":"7296929","preferredDefinition":"ACNS1931 Stratum 11: Efficacy Phase: indeterminate BRAF, no prior Vinblastine prior MEK","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6690ED4-8589-7106-E053-4EBD850AFB1A","latestVersionIndicator":"Yes","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-05-24","modifiedBy":"ONEDATA","dateModified":"2020-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-5FA7-17B6-E053-4EBD850A2842","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"ACNS1931 Stratum 12","valueDescription":"Stratum 12: Efficacy Phase: indeterminate BRAF, prior Vinblastine and MEK","ValueMeaning":{"publicId":"7296928","version":"1","preferredName":"Stratum 12: Efficacy Phase: indeterminate BRAF, prior Vinblastine and MEK","longName":"7296928","preferredDefinition":"ACNS1931 Stratum 12: Efficacy Phase: indeterminate BRAF, prior Vinblastine and MEK","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6690ED4-8566-7106-E053-4EBD850AFB1A","latestVersionIndicator":"Yes","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-05-24","modifiedBy":"ONEDATA","dateModified":"2020-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-5FB1-17B6-E053-4EBD850A2842","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"ACNS1931 Stratum 13","valueDescription":"Stratum 13: Efficacy Phase: indeterminate BRAF, no prior Vinblastine or MEK","ValueMeaning":{"publicId":"7296927","version":"1","preferredName":"Stratum 13: Efficacy Phase: indeterminate BRAF, no prior Vinblastine or MEK","longName":"7296927","preferredDefinition":"ACNS1931 Stratum 13: Efficacy Phase: indeterminate BRAF, no prior Vinblastine or MEK","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6690ED4-8543-7106-E053-4EBD850AFB1A","latestVersionIndicator":"Yes","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-05-24","modifiedBy":"ONEDATA","dateModified":"2020-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-5FBB-17B6-E053-4EBD850A2842","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"ACNS1931 Stratum 2","valueDescription":"Stratum 2: Efficacy Phase: BRAF rearranged, prior Vinblastine no prior MEK","ValueMeaning":{"publicId":"7296922","version":"1","preferredName":"Stratum 2: Efficacy Phase: BRAF rearranged, prior Vinblastine no prior MEK","longName":"7296922","preferredDefinition":"ACNS1931 Stratum 2: Efficacy Phase: BRAF rearranged, prior Vinblastine no prior MEK","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A668D701-26BE-5E80-E053-4EBD850ABC27","latestVersionIndicator":"Yes","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-05-24","modifiedBy":"ONEDATA","dateModified":"2020-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-5FC5-17B6-E053-4EBD850A2842","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"ACNS1931 Stratum 3","valueDescription":"Stratum 3: Efficacy Phase: BRAF rearranged, no prior Vinblastine prior MEK","ValueMeaning":{"publicId":"7296921","version":"1","preferredName":"Stratum 3: Efficacy Phase: BRAF rearranged, no prior Vinblastine prior MEK","longName":"7296921","preferredDefinition":"ACNS1931 Stratum 3: Efficacy Phase: BRAF rearranged, no prior Vinblastine prior MEK","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A668D701-269B-5E80-E053-4EBD850ABC27","latestVersionIndicator":"Yes","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-05-24","modifiedBy":"ONEDATA","dateModified":"2020-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-5FCF-17B6-E053-4EBD850A2842","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"ACNS1931 Stratum 4","valueDescription":"Stratum 4: Efficacy Phase: BRAF rearranged, prior Vinblastine and MEK","ValueMeaning":{"publicId":"7296920","version":"1","preferredName":"Stratum 4: Efficacy Phase: BRAF rearranged, prior Vinblastine and MEK","longName":"7296920","preferredDefinition":"ACNS1931 Stratum 4: Efficacy Phase: BRAF rearranged, prior Vinblastine and MEK","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A668D701-2678-5E80-E053-4EBD850ABC27","latestVersionIndicator":"Yes","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-05-24","modifiedBy":"ONEDATA","dateModified":"2020-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-5FD9-17B6-E053-4EBD850A2842","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"ACNS1931 Stratum 5","valueDescription":"Stratum 5: Efficacy Phase: BRAF rearranged, no prior Vinblastine or MEK","ValueMeaning":{"publicId":"7296926","version":"1","preferredName":"Stratum 5: Efficacy Phase: BRAF rearranged, no prior Vinblastine or MEK","longName":"7296926","preferredDefinition":"ACNS1931 Stratum 5: Efficacy Phase: BRAF rearranged, no prior Vinblastine or MEK","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A668EF71-C37A-5E6B-E053-4EBD850A3C3A","latestVersionIndicator":"Yes","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-05-24","modifiedBy":"ONEDATA","dateModified":"2020-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-5FE3-17B6-E053-4EBD850A2842","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"ACNS1931 Stratum 6","valueDescription":"Stratum 6: Efficacy Phase: no BRAF rearrangement, prior Vinblastine no prior MEK","ValueMeaning":{"publicId":"7296925","version":"1","preferredName":"Stratum 6: Efficacy Phase: no BRAF rearrangement, prior Vinblastine no prior MEK","longName":"7296925","preferredDefinition":"ACNS1931 Stratum 6: Efficacy Phase: no BRAF rearrangement, prior Vinblastine no prior MEK","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A668EF71-C357-5E6B-E053-4EBD850A3C3A","latestVersionIndicator":"Yes","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-05-24","modifiedBy":"ONEDATA","dateModified":"2020-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-5FED-17B6-E053-4EBD850A2842","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"ACNS1931 Stratum 7","valueDescription":"Stratum 7: Efficacy Phase: no BRAF rearrangement, no prior Vinblastine prior MEK","ValueMeaning":{"publicId":"7296924","version":"1","preferredName":"Stratum 7: Efficacy Phase: no BRAF rearrangement, no prior Vinblastine prior MEK","longName":"7296924","preferredDefinition":"ACNS1931 Stratum 7: Efficacy Phase: no BRAF rearrangement, no prior Vinblastine prior MEK","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A668EF71-C334-5E6B-E053-4EBD850A3C3A","latestVersionIndicator":"Yes","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-05-24","modifiedBy":"ONEDATA","dateModified":"2020-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-5FF7-17B6-E053-4EBD850A2842","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"ACNS1931 Stratum 8","valueDescription":"Stratum 8: Efficacy Phase: no BRAF rearrangement, prior Vinblastine and MEK","ValueMeaning":{"publicId":"7296932","version":"1","preferredName":"Stratum 8: Efficacy Phase: no BRAF rearrangement, prior Vinblastine and MEK","longName":"7296932","preferredDefinition":"ACNS1931 Stratum 8: Efficacy Phase: no BRAF rearrangement, prior Vinblastine and MEK","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6690ED4-85F2-7106-E053-4EBD850AFB1A","latestVersionIndicator":"Yes","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-05-24","modifiedBy":"ONEDATA","dateModified":"2020-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-6001-17B6-E053-4EBD850A2842","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"ACNS1931 Stratum 9","valueDescription":"Stratum 9: Efficacy Phase: no BRAF rearrangement, no prior Vinblastine or MEK","ValueMeaning":{"publicId":"7296931","version":"1","preferredName":"Stratum 9: Efficacy Phase: no BRAF rearrangement, no prior Vinblastine or MEK","longName":"7296931","preferredDefinition":"ACNS1931 Stratum 9: Efficacy Phase: no BRAF rearrangement, no prior Vinblastine or MEK","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6690ED4-85CF-7106-E053-4EBD850AFB1A","latestVersionIndicator":"Yes","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-05-24","modifiedBy":"ONEDATA","dateModified":"2020-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF4A16CC-600B-17B6-E053-4EBD850A2842","beginDate":"2020-05-24","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"ONEDATA","dateModified":"2020-09-14","deletedIndicator":"No"},{"value":"PEPN1924 Screening","valueDescription":"PEPN1924 Screening","ValueMeaning":{"publicId":"7490600","version":"1","preferredName":"PEPN1924 Screening","longName":"7490600","preferredDefinition":"PEPN1924 Screening","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B34D2E51-0F63-5001-E053-4EBD850AF9CC","latestVersionIndicator":"Yes","beginDate":"2020-11-04","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-11-04","modifiedBy":"ONEDATA","dateModified":"2020-11-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B3781738-0480-28B8-E053-4EBD850A8772","beginDate":"2020-11-06","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-11-06","modifiedBy":"ONEDATA","dateModified":"2020-11-06","deletedIndicator":"No"},{"value":"PEPN1924 Stratum 1","valueDescription":"Patients with recurrent HER2+ Osteosarcoma >= 12 years of age and <= 39 years of age","ValueMeaning":{"publicId":"7490571","version":"1","preferredName":"Patients with recurrent HER2+ Osteosarcoma >= 12 years of age and <= 39 years of age","longName":"7490571","preferredDefinition":"PEPN1924 Stratum 1: Patients with recurrent HER2+ Osteosarcoma >= 12 years of age and <= 39 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B34D1DB7-D4FE-0583-E053-4EBD850AE6C0","latestVersionIndicator":"Yes","beginDate":"2020-11-04","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-11-04","modifiedBy":"ONEDATA","dateModified":"2020-11-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B34D1DB7-D517-0583-E053-4EBD850AE6C0","beginDate":"2020-11-04","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2020-11-04","modifiedBy":"ONEDATA","dateModified":"2020-11-04","deletedIndicator":"No"},{"value":"PEPN2011 PK Cohort 2","valueDescription":"Patients with relapsed or refractory solid tumors less than 12 years old","ValueMeaning":{"publicId":"7629229","version":"1","preferredName":"Patients with relapsed or refractory solid tumors less than 12 years old","longName":"7629229","preferredDefinition":"PEPN2011 PK Cohort 2: Patients with relapsed or refractory solid tumors less than 12 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8E4A12-2023-726C-E053-4EBD850A2C2B","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF8E4A12-203C-726C-E053-4EBD850A2C2B","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","deletedIndicator":"No"},{"value":"PEPN2011 PK Cohort 1","valueDescription":"Patients with relapsed or refractory solid tumors greater than or equal to 12 years old","ValueMeaning":{"publicId":"7629230","version":"1","preferredName":"Patients with relapsed or refractory solid tumors greater than or equal to 12 years old","longName":"7629230","preferredDefinition":"PEPN2011 PK Cohort 1: Patients with relapsed or refractory solid tumors greater than or equal to 12 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8E4A12-2046-726C-E053-4EBD850A2C2B","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF8E4A12-205F-726C-E053-4EBD850A2C2B","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","deletedIndicator":"No"},{"value":"PEPN2011 Part B6","valueDescription":"Patients with recurrent or refractory tumors with Wnt pathway aberrations","ValueMeaning":{"publicId":"7629231","version":"1","preferredName":"Patients with recurrent or refractory tumors with Wnt pathway aberrations","longName":"7629231","preferredDefinition":"PEPN2011 Part B6: Patients with recurrent or refractory tumors with Wnt pathway aberrations","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8E4A12-2069-726C-E053-4EBD850A2C2B","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF8E4A12-2082-726C-E053-4EBD850A2C2B","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","deletedIndicator":"No"},{"value":"PEPN2011 Part B5","valueDescription":"Patients with recurrent or refractory Wilms tumors","ValueMeaning":{"publicId":"7629232","version":"1","preferredName":"Patients with recurrent or refractory Wilms tumors","longName":"7629232","preferredDefinition":"PEPN2011 Part B5: Patients with recurrent or refractory Wilms tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8E4A12-208C-726C-E053-4EBD850A2C2B","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF8E4A12-20A5-726C-E053-4EBD850A2C2B","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","deletedIndicator":"No"},{"value":"PEPN2011 Part B4","valueDescription":"Patients with recurrent or refractory liver tumors","ValueMeaning":{"publicId":"7629233","version":"1","preferredName":"Patients with recurrent or refractory liver tumors","longName":"7629233","preferredDefinition":"PEPN2011 Part B4: Patients with recurrent or refractory liver tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8E4A12-20AF-726C-E053-4EBD850A2C2B","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF8E4A12-20C8-726C-E053-4EBD850A2C2B","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","deletedIndicator":"No"},{"value":"PEPN2011 Part B3","valueDescription":"Patients with recurrent or refractory osteosarcoma","ValueMeaning":{"publicId":"7629234","version":"1","preferredName":"Patients with recurrent or refractory osteosarcoma","longName":"7629234","preferredDefinition":"PEPN2011 Part B3: Patients with recurrent or refractory osteosarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8E4A12-20D2-726C-E053-4EBD850A2C2B","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF8E4A12-20EB-726C-E053-4EBD850A2C2B","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","deletedIndicator":"No"},{"value":"PEPN2011 Part B2","valueDescription":"Patients with recurrent or refractory desmoid tumors","ValueMeaning":{"publicId":"7629235","version":"1","preferredName":"Patients with recurrent or refractory desmoid tumors","longName":"7629235","preferredDefinition":"PEPN2011 Part B2: Patients with recurrent or refractory desmoid tumors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8E4A12-20F5-726C-E053-4EBD850A2C2B","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF8E4A12-210E-726C-E053-4EBD850A2C2B","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","deletedIndicator":"No"},{"value":"PEPN2011 Part B1","valueDescription":"Patients with recurrent or refractory Ewing Sarcoma","ValueMeaning":{"publicId":"7629236","version":"1","preferredName":"Patients with recurrent or refractory Ewing Sarcoma","longName":"7629236","preferredDefinition":"PEPN2011 Part B1: Patients with recurrent or refractory Ewing Sarcoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8E4A12-2118-726C-E053-4EBD850A2C2B","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF8E4A12-2131-726C-E053-4EBD850A2C2B","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","deletedIndicator":"No"},{"value":"PEPN2011 Part A2","valueDescription":"Patients with relapsed or refractory solid tumors including non-Hodgkin lymphoma and desmoid tumors with or without bone marrow involvement.","ValueMeaning":{"publicId":"7629237","version":"1","preferredName":"Patients with relapsed or refractory solid tumors including non-Hodgkin lymphoma and desmoid tumors with or without bone marrow involvement.","longName":"7629237","preferredDefinition":"PEPN2011 Part A2: Patients with relapsed or refractory solid tumors including non-Hodgkin lymphoma and desmoid tumors with or without bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8E4A12-213B-726C-E053-4EBD850A2C2B","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF8E4A12-2154-726C-E053-4EBD850A2C2B","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","deletedIndicator":"No"},{"value":"PEPN2011 Part A1","valueDescription":"Patients with relapsed or refractory solid tumors including non-Hodgkin lymphoma and desmoid tumors without bone marrow involvement.","ValueMeaning":{"publicId":"7629238","version":"1","preferredName":"Patients with relapsed or refractory solid tumors including non-Hodgkin lymphoma and desmoid tumors without bone marrow involvement.","longName":"7629238","preferredDefinition":"PEPN2011 Part A1: Patients with relapsed or refractory solid tumors including non-Hodgkin lymphoma and desmoid tumors without bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8E4A12-215E-726C-E053-4EBD850A2C2B","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF8E4A12-2177-726C-E053-4EBD850A2C2B","beginDate":"2021-04-09","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-04-09","modifiedBy":"ONEDATA","dateModified":"2021-04-09","deletedIndicator":"No"},{"value":"PEPN2111 Part B2:","valueDescription":"PEPN2111 Part B2:","ValueMeaning":{"publicId":"7580830","version":"1","preferredName":"PEPN2111 Part B2:","longName":"7580830","preferredDefinition":"Patients with relapsed or refractory osteosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBA583A0-26DE-17EC-E053-4EBD850A876D","latestVersionIndicator":"Yes","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBA583A0-26F7-17EC-E053-4EBD850A876D","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","deletedIndicator":"No"},{"value":"PEPN2111 Part B1:","valueDescription":"PEPN2111 Part B1:","ValueMeaning":{"publicId":"7580831","version":"1","preferredName":"PEPN2111 Part B1:","longName":"7580831","preferredDefinition":"Patients with progressive or recurrent DIPG and other H3 K27Mmutant diffuse midline gliomas previously treated with radiation therapy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBA583A0-2701-17EC-E053-4EBD850A876D","latestVersionIndicator":"Yes","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBA583A0-271A-17EC-E053-4EBD850A876D","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","deletedIndicator":"No"},{"value":"PEPN2111 Part A2:","valueDescription":"PEPN2111 Part A2:","ValueMeaning":{"publicId":"7580832","version":"1","preferredName":"PEPN2111 Part A2:","longName":"7580832","preferredDefinition":"Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or known CNS metastases with or without bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBA583A0-2724-17EC-E053-4EBD850A876D","latestVersionIndicator":"Yes","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBA583A0-273D-17EC-E053-4EBD850A876D","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","deletedIndicator":"No"},{"value":"PEPN2111 Part A1:","valueDescription":"PEPN2111 Part A1","ValueMeaning":{"publicId":"7580833","version":"1","preferredName":"PEPN2111 Part A1","longName":"7580833","preferredDefinition":"Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or known CNS metastases without bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBA583A0-2747-17EC-E053-4EBD850A876D","latestVersionIndicator":"Yes","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBA583A0-2760-17EC-E053-4EBD850A876D","beginDate":"2021-02-18","endDate":null,"createdBy":"RODELAA","dateCreated":"2021-02-18","modifiedBy":"ONEDATA","dateModified":"2021-02-18","deletedIndicator":"No"},{"value":"PEPN2011 Part B5b","valueDescription":"Patients with recurrent or refractory Wilms tumors less than 22 years old","ValueMeaning":{"publicId":"7716498","version":"1","preferredName":"Patients with recurrent or refractory Wilms tumors less than 22 years old","longName":"7716498","preferredDefinition":"PEPN2011 Part B5b: Patients with recurrent or refractory Wilms tumors less than 22 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6299E89-351B-573E-E053-4EBD850ADB7E","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6299E89-3534-573E-E053-4EBD850ADB7E","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2011 Part B6b","valueDescription":"Patients with recurrent or refractory tumors with Wnt pathway aberrations less than 22 years old","ValueMeaning":{"publicId":"7716496","version":"1","preferredName":"Patients with recurrent or refractory tumors with Wnt pathway aberrations less than 22 years old","longName":"7716496","preferredDefinition":"PEPN2011 Part B6b: Patients with recurrent or refractory tumors with Wnt pathway aberrations less than 22 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6299E89-34D5-573E-E053-4EBD850ADB7E","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6299E89-34EE-573E-E053-4EBD850ADB7E","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2011 Part B6a","valueDescription":"Patients with recurrent or refractory tumors with Wnt pathway aberrations greater than or equal to 22 years old","ValueMeaning":{"publicId":"7716497","version":"1","preferredName":"Patients with recurrent or refractory tumors with Wnt pathway aberrations greater than or equal to 22 years old","longName":"7716497","preferredDefinition":"PEPN2011 Part B6a: Patients with recurrent or refractory tumors with Wnt pathway aberrations greater than or equal to 22 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6299E89-34F8-573E-E053-4EBD850ADB7E","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6299E89-3511-573E-E053-4EBD850ADB7E","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2011 Part B5a","valueDescription":"Patients with recurrent or refractory Wilms tumors greater than or equal to 22 years old","ValueMeaning":{"publicId":"7716499","version":"1","preferredName":"Patients with recurrent or refractory Wilms tumors greater than or equal to 22 years old","longName":"7716499","preferredDefinition":"PEPN2011 Part B5a: Patients with recurrent or refractory Wilms tumors greater than or equal to 22 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6299E89-353E-573E-E053-4EBD850ADB7E","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6299E89-3557-573E-E053-4EBD850ADB7E","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2011 Part B4b","valueDescription":"Patients with recurrent or refractory liver tumors less than 22 years old","ValueMeaning":{"publicId":"7716500","version":"1","preferredName":"Patients with recurrent or refractory liver tumors less than 22 years old","longName":"7716500","preferredDefinition":"PEPN2011 Part B4b: Patients with recurrent or refractory liver tumors less than 22 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6299E89-3561-573E-E053-4EBD850ADB7E","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6299E89-357A-573E-E053-4EBD850ADB7E","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2011 Part B4a","valueDescription":"Patients with recurrent or refractory liver tumors greater than or equal to 22 years old","ValueMeaning":{"publicId":"7716501","version":"1","preferredName":"Patients with recurrent or refractory liver tumors greater than or equal to 22 years old","longName":"7716501","preferredDefinition":"PEPN2011 Part B4a: Patients with recurrent or refractory liver tumors greater than or equal to 22 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6299E89-3584-573E-E053-4EBD850ADB7E","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6299E89-359D-573E-E053-4EBD850ADB7E","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2011 Part B3b","valueDescription":"Patients with recurrent or refractory osteosarcoma less than 22 years old","ValueMeaning":{"publicId":"7716502","version":"1","preferredName":"Patients with recurrent or refractory osteosarcoma less than 22 years old","longName":"7716502","preferredDefinition":"PEPN2011 Part B3b: Patients with recurrent or refractory osteosarcoma less than 22 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6299E89-35A7-573E-E053-4EBD850ADB7E","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6299E89-35C0-573E-E053-4EBD850ADB7E","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2011 Part B3a","valueDescription":"Patients with recurrent or refractory osteosarcoma greater than or equal to 22 years old","ValueMeaning":{"publicId":"7716503","version":"1","preferredName":"Patients with recurrent or refractory osteosarcoma greater than or equal to 22 years old","longName":"7716503","preferredDefinition":"PEPN2011 Part B3a: Patients with recurrent or refractory osteosarcoma greater than or equal to 22 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6299E89-35CA-573E-E053-4EBD850ADB7E","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6299E89-35E3-573E-E053-4EBD850ADB7E","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2011 Part B2b","valueDescription":"Patients with recurrent or refractory desmoid tumors less than 22 years old","ValueMeaning":{"publicId":"7716504","version":"1","preferredName":"Patients with recurrent or refractory desmoid tumors less than 22 years old","longName":"7716504","preferredDefinition":"PEPN2011 Part B2b: Patients with recurrent or refractory desmoid tumors less than 22 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6299E89-35ED-573E-E053-4EBD850ADB7E","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6299E89-3606-573E-E053-4EBD850ADB7E","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2011 Part B2a","valueDescription":"Patients with recurrent or refractory desmoid tumors greater than or equal to 22 years old","ValueMeaning":{"publicId":"7716505","version":"1","preferredName":"Patients with recurrent or refractory desmoid tumors greater than or equal to 22 years old","longName":"7716505","preferredDefinition":"PEPN2011 Part B2a: Patients with recurrent or refractory desmoid tumors greater than or equal to 22 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6299E89-3610-573E-E053-4EBD850ADB7E","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6299E89-3629-573E-E053-4EBD850ADB7E","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2011 Part B1b","valueDescription":"Patients with recurrent or refractory Ewing Sarcoma less than 22 years old","ValueMeaning":{"publicId":"7716506","version":"1","preferredName":"Patients with recurrent or refractory Ewing Sarcoma less than 22 years old","longName":"7716506","preferredDefinition":"PEPN2011 Part B1b: Patients with recurrent or refractory Ewing Sarcoma less than 22 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6299E89-3633-573E-E053-4EBD850ADB7E","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6299E89-364C-573E-E053-4EBD850ADB7E","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2011 Part B1a","valueDescription":"Patients with recurrent or refractory Ewing Sarcoma greater than or equal to 22 years old","ValueMeaning":{"publicId":"7716507","version":"1","preferredName":"Patients with recurrent or refractory Ewing Sarcoma greater than or equal to 22 years old","longName":"7716507","preferredDefinition":"PEPN2011 Part B1a: Patients with recurrent or refractory Ewing Sarcoma greater than or equal to 22 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6299E89-3656-573E-E053-4EBD850ADB7E","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6299E89-366F-573E-E053-4EBD850ADB7E","beginDate":"2021-07-02","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2111 Part B2","valueDescription":"PEPN2111 Part B2 v2","ValueMeaning":{"publicId":"7716524","version":"1","preferredName":"PEPN2111 Part B2 v2","longName":"7716524","preferredDefinition":"Patients with relapsed or refractory osteosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C62B592E-C0AB-08EB-E053-4EBD850A2A03","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C62B592E-C0C4-08EB-E053-4EBD850A2A03","beginDate":"2021-07-02","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2111 Part A2","valueDescription":"PEPN2111 Part A2 v2","ValueMeaning":{"publicId":"7716522","version":"1","preferredName":"PEPN2111 Part A2 v2","longName":"7716522","preferredDefinition":"Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or metastases with or without bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6247883-6AAA-088A-E053-4EBD850AA030","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6247883-6AC3-088A-E053-4EBD850AA030","beginDate":"2021-07-02","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2111 Part A1","valueDescription":"PEPN2111 Part A1 v2","ValueMeaning":{"publicId":"7716520","version":"1","preferredName":"PEPN2111 Part A1 v2","longName":"7716520","preferredDefinition":"Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or metastases without bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C62B3855-4425-7AB8-E053-4EBD850A8D83","latestVersionIndicator":"Yes","beginDate":"2021-07-02","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C62B3855-443E-7AB8-E053-4EBD850A8D83","beginDate":"2021-07-02","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-02","modifiedBy":"ONEDATA","dateModified":"2021-07-02","deletedIndicator":"No"},{"value":"PEPN2111 Part B2","valueDescription":"Patients with relapsed or refractory osteosarcoma.","ValueMeaning":{"publicId":"7717188","version":"1","preferredName":"Patients with relapsed or refractory osteosarcoma.","longName":"7717188","preferredDefinition":"PEPN2111 Part B2: Patients with relapsed or refractory osteosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C67D9C8D-FA2F-5B58-E053-4EBD850A7A0A","latestVersionIndicator":"Yes","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C67D9C8D-FA48-5B58-E053-4EBD850A7A0A","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","deletedIndicator":"No"},{"value":"PEPN2111 Part B1","valueDescription":"Patients with progressive or recurrent DIPG and other H3 K27Mmutant diffuse midline gliomas previously treated with radiation therapy.","ValueMeaning":{"publicId":"7717189","version":"1","preferredName":"PEPN2111 Part B1: Patients with progressive or recurrent DIPG and other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy.","longName":"7717189v1.00","preferredDefinition":"PEPN2111 Part B1: Patients with progressive or recurrent DIPG and other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C67D9C8D-FA52-5B58-E053-4EBD850A7A0A","latestVersionIndicator":"Yes","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"GDEEN","dateModified":"2023-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C67D9C8D-FA6B-5B58-E053-4EBD850A7A0A","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","deletedIndicator":"No"},{"value":"PEPN2111 Part A2","valueDescription":"Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or metastases with or without bone marrow involvement.","ValueMeaning":{"publicId":"7717190","version":"1","preferredName":"Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or metastases with or without bone marrow involvement.","longName":"7717190","preferredDefinition":"PEPN2111 Part A2: Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or metastases with or without bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C67D9C8D-FA75-5B58-E053-4EBD850A7A0A","latestVersionIndicator":"Yes","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C67D9C8D-FA8E-5B58-E053-4EBD850A7A0A","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","deletedIndicator":"No"},{"value":"PEPN2111 Part A1","valueDescription":"Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or metastases without bone marrow involvement.","ValueMeaning":{"publicId":"7717191","version":"1","preferredName":"Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or metastases without bone marrow involvement.","longName":"7717191","preferredDefinition":"PEPN2111 Part A1: Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or metastases without bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C67D9C8D-FA98-5B58-E053-4EBD850A7A0A","latestVersionIndicator":"Yes","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C67D9C8D-FAB1-5B58-E053-4EBD850A7A0A","beginDate":"2021-07-06","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","deletedIndicator":"No"},{"value":"PEPN2111 PK Cohort 1","valueDescription":"Patients with relapsed or refractory solid tumors less than 12 years old.","ValueMeaning":{"publicId":"7767245","version":"1","preferredName":"Patients with relapsed or refractory solid tumors less than 12 years old.","longName":"7767245","preferredDefinition":"PEPN2111 PK Cohort 1: Patients with relapsed or refractory solid tumors less than 12 years old.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9C5D88F-1746-5627-E053-4EBD850AF475","latestVersionIndicator":"Yes","beginDate":"2021-08-17","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-08-17","modifiedBy":"ONEDATA","dateModified":"2021-08-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C9C5D88F-175F-5627-E053-4EBD850AF475","beginDate":"2021-08-17","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-08-17","modifiedBy":"ONEDATA","dateModified":"2021-08-17","deletedIndicator":"No"},{"value":"PEPN2111 PK Cohort 2","valueDescription":"Patients with relapsed or refractory solid tumors greater than or equal to 12 years old.","ValueMeaning":{"publicId":"7767244","version":"1","preferredName":"Patients with relapsed or refractory solid tumors greater than or equal to 12 years old.","longName":"7767244","preferredDefinition":"PEPN2111 PK Cohort 2: Patients with relapsed or refractory solid tumors greater than or equal to 12 years old.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9C5D88F-1723-5627-E053-4EBD850AF475","latestVersionIndicator":"Yes","beginDate":"2021-08-17","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-08-17","modifiedBy":"ONEDATA","dateModified":"2021-08-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C9C5D88F-173C-5627-E053-4EBD850AF475","beginDate":"2021-08-17","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-08-17","modifiedBy":"ONEDATA","dateModified":"2021-08-17","deletedIndicator":"No"},{"value":"PEPN2112 PK Cohort 2","valueDescription":"Patients with recurrent or refractory solid tumors greater than or equal to 12 years old.","ValueMeaning":{"publicId":"7802092","version":"1","preferredName":"Patients with recurrent or refractory solid tumors greater than or equal to 12 years old.","longName":"7802092","preferredDefinition":"PEPN2112 PK Cohort 2: Patients with recurrent or refractory solid tumors greater than or equal to 12 years old.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFE4C07E-4838-5DFC-E053-4EBD850AA7C7","latestVersionIndicator":"Yes","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CFE4C07E-4851-5DFC-E053-4EBD850AA7C7","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","deletedIndicator":"No"},{"value":"PEPN2112 PK Cohort 1","valueDescription":"Patients with recurrent or refractory solid tumors less than 12 years old.","ValueMeaning":{"publicId":"7802093","version":"1","preferredName":"Patients with recurrent or refractory solid tumors less than 12 years old.","longName":"7802093","preferredDefinition":"PEPN2112 PK Cohort 1: Patients with recurrent or refractory solid tumors less than 12 years old.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFE4C07E-485B-5DFC-E053-4EBD850AA7C7","latestVersionIndicator":"Yes","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CFE4C07E-4874-5DFC-E053-4EBD850AA7C7","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","deletedIndicator":"No"},{"value":"PEPN2112 Part B3b","valueDescription":"Patients with any (non-CNS primary) solid tumor including lymphoma with inactivation of any of the DNA Damage Repair (DDR) genes. Age less than 18 years.","ValueMeaning":{"publicId":"7802094","version":"1","preferredName":"Patients with any (non-CNS primary) solid tumor including lymphoma with inactivation of any of the DNA Damage Repair (DDR) genes. Age less than 18 years.","longName":"7802094","preferredDefinition":"PEPN2112 Part B3b: Patients with any (non-CNS primary) solid tumor including lymphoma with inactivation of any of the DNA Damage Repair (DDR) genes. Age less than 18 years.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFE4C07E-487E-5DFC-E053-4EBD850AA7C7","latestVersionIndicator":"Yes","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CFE4C07E-4897-5DFC-E053-4EBD850AA7C7","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","deletedIndicator":"No"},{"value":"PEPN2112 Part B2b","valueDescription":"Patients with alveolar rhabdomyosarcoma (ARMS) with the PAX3-FOXO1 fusion. Age less than 18 years.","ValueMeaning":{"publicId":"7802096","version":"1","preferredName":"Patients with alveolar rhabdomyosarcoma (ARMS) with the PAX3-FOXO1 fusion. Age less than 18 years.","longName":"7802096","preferredDefinition":"PEPN2112 Part B2b: Patients with alveolar rhabdomyosarcoma (ARMS) with the PAX3-FOXO1 fusion. Age less than 18 years.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFE4C07E-48C4-5DFC-E053-4EBD850AA7C7","latestVersionIndicator":"Yes","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CFE4C07E-48DD-5DFC-E053-4EBD850AA7C7","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","deletedIndicator":"No"},{"value":"PEPN2112 Part B2a","valueDescription":"Patients with alveolar rhabdomyosarcoma (ARMS) with the PAX3-FOXO1 fusion. Age greater than or equal to 18 years.","ValueMeaning":{"publicId":"7802097","version":"1","preferredName":"Patients with alveolar rhabdomyosarcoma (ARMS) with the PAX3-FOXO1 fusion. Age greater than or equal to 18 years.","longName":"7802097","preferredDefinition":"PEPN2112 Part B2a: Patients with alveolar rhabdomyosarcoma (ARMS) with the PAX3-FOXO1 fusion. Age greater than or equal to 18 years.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFE4C07E-48E7-5DFC-E053-4EBD850AA7C7","latestVersionIndicator":"Yes","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CFE4C07E-4900-5DFC-E053-4EBD850AA7C7","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","deletedIndicator":"No"},{"value":"PEPN2112 Part B1b","valueDescription":"Patients with any Ewing Sarcoma or any EWS-fusion positive solid tumor. Age less than 18 years.","ValueMeaning":{"publicId":"7802098","version":"1","preferredName":"Patients with any Ewing Sarcoma or any EWS-fusion positive solid tumor. Age less than 18 years.","longName":"7802098","preferredDefinition":"PEPN2112 Part B1b: Patients with any Ewing Sarcoma or any EWS-fusion positive solid tumor. Age less than 18 years.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFE4C07E-490A-5DFC-E053-4EBD850AA7C7","latestVersionIndicator":"Yes","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CFE4C07E-4923-5DFC-E053-4EBD850AA7C7","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","deletedIndicator":"No"},{"value":"PEPN2112 Part B1a","valueDescription":"Patients with any Ewing Sarcoma or any EWS-fusion positive solid tumor. Age greater than or equal to 18 years.","ValueMeaning":{"publicId":"7802099","version":"1","preferredName":"Patients with any Ewing Sarcoma or any EWS-fusion positive solid tumor. Age greater than or equal to 18 years.","longName":"7802099","preferredDefinition":"PEPN2112 Part B1a: Patients with any Ewing Sarcoma or any EWS-fusion positive solid tumor. Age greater than or equal to 18 years.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFE4C07E-492D-5DFC-E053-4EBD850AA7C7","latestVersionIndicator":"Yes","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CFE4C07E-4946-5DFC-E053-4EBD850AA7C7","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","deletedIndicator":"No"},{"value":"PEPN2112 Part A2","valueDescription":"Patients with specified recurrent or refractory solid tumors or lymphomas with or without bone marrow involvement. Age 12 months to less than 18 years.","ValueMeaning":{"publicId":"7802100","version":"1","preferredName":"Patients with specified recurrent or refractory solid tumors or lymphomas with or without bone marrow involvement. Age 12 months to less than 18 years.","longName":"7802100","preferredDefinition":"PEPN2112 Part A2: Patients with specified recurrent or refractory solid tumors or lymphomas with or without bone marrow involvement. Age 12 months to less than 18 years.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFE4C07E-4950-5DFC-E053-4EBD850AA7C7","latestVersionIndicator":"Yes","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CFE4C07E-4969-5DFC-E053-4EBD850AA7C7","beginDate":"2021-11-03","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","deletedIndicator":"No"},{"value":"Dose-finding","valueDescription":"Dose-finding","ValueMeaning":{"publicId":"7808479","version":"1","preferredName":"Dose-finding","longName":"7808479","preferredDefinition":"Drug titration to find ideal dose level","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D00AE5E3-6ED4-359A-E053-4EBD850A9CE7","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-11-05","modifiedBy":"ONEDATA","dateModified":"2021-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D00AE5E3-6EF0-359A-E053-4EBD850A9CE7","beginDate":"2021-11-05","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-11-05","modifiedBy":"ONEDATA","dateModified":"2021-11-05","deletedIndicator":"No"},{"value":"Efficacy Stratum 3: HGG","valueDescription":"Efficacy Stratum 3: HGG","ValueMeaning":{"publicId":"7847772","version":"1","preferredName":"Efficacy Stratum 3: HGG","longName":"7847772","preferredDefinition":"Efficacy Stratum 3: HGG","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D22BF466-970A-4D6E-E053-4EBD850AEF26","latestVersionIndicator":"Yes","beginDate":"2021-12-02","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-12-02","modifiedBy":"ONEDATA","dateModified":"2021-12-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D22BF466-9723-4D6E-E053-4EBD850AEF26","beginDate":"2021-12-02","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-12-02","modifiedBy":"ONEDATA","dateModified":"2021-12-02","deletedIndicator":"No"},{"value":"Efficacy Stratum 2: DMG","valueDescription":"Efficacy Stratum 2: DMG","ValueMeaning":{"publicId":"7847773","version":"1","preferredName":"Efficacy Stratum 2: DMG","longName":"7847773","preferredDefinition":"Efficacy Stratum 2: DMG","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D22BF466-972D-4D6E-E053-4EBD850AEF26","latestVersionIndicator":"Yes","beginDate":"2021-12-02","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-12-02","modifiedBy":"ONEDATA","dateModified":"2021-12-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D22BF466-9746-4D6E-E053-4EBD850AEF26","beginDate":"2021-12-02","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-12-02","modifiedBy":"ONEDATA","dateModified":"2021-12-02","deletedIndicator":"No"},{"value":"Efficacy Stratum 1: DIPG","valueDescription":"Efficacy Stratum 1: DIPG","ValueMeaning":{"publicId":"7847774","version":"1","preferredName":"Efficacy Stratum 1: DIPG","longName":"7847774","preferredDefinition":"Efficacy Stratum 1: DIPG","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D22BF466-9750-4D6E-E053-4EBD850AEF26","latestVersionIndicator":"Yes","beginDate":"2021-12-02","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-12-02","modifiedBy":"ONEDATA","dateModified":"2021-12-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D22BF466-9769-4D6E-E053-4EBD850AEF26","beginDate":"2021-12-02","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-12-02","modifiedBy":"ONEDATA","dateModified":"2021-12-02","deletedIndicator":"No"},{"value":"Efficacy Stratum 3","valueDescription":"Efficacy Stratum 3","ValueMeaning":{"publicId":"7808480","version":"1","preferredName":"Efficacy Stratum 3","longName":"7808480","preferredDefinition":"Stratum to determine the efficacy of a drug","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D00E6D89-A430-4F88-E053-4EBD850A5914","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-11-05","modifiedBy":"ONEDATA","dateModified":"2021-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D00E6D89-A44C-4F88-E053-4EBD850A5914","beginDate":"2021-11-05","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-11-05","modifiedBy":"ONEDATA","dateModified":"2021-11-05","deletedIndicator":"No"},{"value":"Efficacy Stratum 2","valueDescription":"Efficacy Stratum 2","ValueMeaning":{"publicId":"7808481","version":"1","preferredName":"Efficacy Stratum 2","longName":"7808481","preferredDefinition":"Stratum to determine the efficacy of a drug","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D00E6D89-A456-4F88-E053-4EBD850A5914","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-11-05","modifiedBy":"ONEDATA","dateModified":"2021-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D00E6D89-A472-4F88-E053-4EBD850A5914","beginDate":"2021-11-05","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-11-05","modifiedBy":"ONEDATA","dateModified":"2021-11-05","deletedIndicator":"No"},{"value":"Efficacy Stratum 1","valueDescription":"Efficacy Stratum 1","ValueMeaning":{"publicId":"7808482","version":"1","preferredName":"Efficacy Stratum 1","longName":"7808482","preferredDefinition":"Stratum to determine the efficacy of a drug","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D00E6D89-A47C-4F88-E053-4EBD850A5914","latestVersionIndicator":"Yes","beginDate":"2021-11-05","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-11-05","modifiedBy":"ONEDATA","dateModified":"2021-11-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D00E6D89-A498-4F88-E053-4EBD850A5914","beginDate":"2021-11-05","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-11-05","modifiedBy":"ONEDATA","dateModified":"2021-11-05","deletedIndicator":"No"},{"value":"PEPN2112 Part A1","valueDescription":"Patients with specified recurrent or refractory solid tumors or lymphomas without bone marrow involvement. Age 12 months to less than 18 years.","ValueMeaning":{"publicId":"7817692","version":"1","preferredName":"Patients with specified recurrent or refractory solid tumors or lymphomas without bone marrow involvement. Age 12 months to less than 18 years.","longName":"7817692","preferredDefinition":"PEPN2112 Part A1: Patients with specified recurrent or refractory solid tumors or lymphomas without bone marrow involvement. Age 12 months to less than 18 years.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0500EE9-6394-2919-E053-4EBD850A04A2","latestVersionIndicator":"Yes","beginDate":"2021-11-08","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-08","modifiedBy":"ONEDATA","dateModified":"2021-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D0500EE9-63AD-2919-E053-4EBD850A04A2","beginDate":"2021-11-08","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-08","modifiedBy":"ONEDATA","dateModified":"2021-11-08","deletedIndicator":"No"},{"value":"PEPN2112 Part B3a","valueDescription":"Patients with any (non-CNS primary) solid tumor including lymphoma with inactivation of any of the DNA Damage Repair (DDR) genes. Age greater than or equal to 18 years.","ValueMeaning":{"publicId":"7817694","version":"1","preferredName":"Patients with any (non-CNS primary) solid tumor including lymphoma with inactivation of any of the DNA Damage Repair (DDR) genes. Age greater than or equal to 18 years.","longName":"7817694","preferredDefinition":"PEPN2112 Part B3a: Patients with any (non-CNS primary) solid tumor including lymphoma with inactivation of any of the DNA Damage Repair (DDR) genes. Age greater than or equal to 18 years.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0500EE9-63CE-2919-E053-4EBD850A04A2","latestVersionIndicator":"Yes","beginDate":"2021-11-08","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-08","modifiedBy":"ONEDATA","dateModified":"2021-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D0500EE9-63E7-2919-E053-4EBD850A04A2","beginDate":"2021-11-08","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2021-11-08","modifiedBy":"ONEDATA","dateModified":"2021-11-08","deletedIndicator":"No"},{"value":"PEPN2113 PK Cohort 2","valueDescription":"Patients with recurrent or refractory AML, MDS, or MPAL without restrictions on heme evaluability less than 12 years old","ValueMeaning":{"publicId":"10471906","version":"1","preferredName":"PEPN2113 PK Cohort 2: Patients with recurrent or refractory AML, tAML, MDS, tMDS, or MPAL greater than or equal to 1 year and less than 12 years old","longName":"10471906v1.00","preferredDefinition":"PEPN2113 PK Cohort 2: Patients with recurrent or refractory AML, tAML, MDS, tMDS, or MPAL greater than or equal to 1 year and less than 12 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E10A6ABC-5BED-2FAE-E053-731AD00A4F5C","latestVersionIndicator":"Yes","beginDate":"2022-06-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-15","modifiedBy":"GDEEN","dateModified":"2023-04-04","changeDescription":null,"administrativeNotes":"2023.3.23 Alt VM added per ticket request CADSR0002207. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DD96EBD6-3812-0E80-E053-4EBD850A7E1B","beginDate":"2022-04-26","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-26","modifiedBy":"KUMMEROA","dateModified":"2022-06-15","deletedIndicator":"No"},{"value":"PEPN2113 PK Cohort 1","valueDescription":"Patients with recurrent or refractory AML, MDS, or MPAL without restrictions on heme evaluability greater than or equal to 12 years old","ValueMeaning":{"publicId":"10471905","version":"1","preferredName":"PEPN2113 PK Cohort 1: Patients with recurrent or refractory AML, tAML, MDS, tMDS, or MPAL greater than or equal to 12 years and less than 18 years old","longName":"10471905v1.00","preferredDefinition":"PEPN2113 PK Cohort 1: Patients with recurrent or refractory AML, tAML, MDS, tMDS, or MPAL greater than or equal to 12 years and less than 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E10A6ABC-5BEC-2FAE-E053-731AD00A4F5C","latestVersionIndicator":"Yes","beginDate":"2022-06-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-15","modifiedBy":"GDEEN","dateModified":"2023-04-04","changeDescription":null,"administrativeNotes":"2023.3.23 Alt VM added per ticket request CADSR0002207. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DD96EBD6-3835-0E80-E053-4EBD850A7E1B","beginDate":"2022-04-26","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-26","modifiedBy":"KUMMEROA","dateModified":"2022-06-15","deletedIndicator":"No"},{"value":"PEPN2113 Stratum 1","valueDescription":"Patients with AML, therapy-related AML, MDS, or MPAL that expresses E-selectin ligand and is 2nd or greater relapse or refractory to relapse therapy","ValueMeaning":{"publicId":"10471904","version":"1","preferredName":"Patients with AML, tAML, MDS, tMDS, or MPAL that expresses E-selectin ligand and is 2nd or greater relapse or refractory to relapse therapy","longName":"10471904v1.00","preferredDefinition":"PEPN2113 Stratum 1: Patients with AML, tAML, MDS, tMDS, or MPAL that expresses E-selectin ligand and is 2nd or greater relapse or refractory to relapse therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E10A6ABC-5BEB-2FAE-E053-731AD00A4F5C","latestVersionIndicator":"Yes","beginDate":"2022-06-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-15","modifiedBy":"KUMMEROA","dateModified":"2023-03-30","changeDescription":null,"administrativeNotes":"2023.3.30 Alt VM added per ticket request CADSR0002245. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DD96EBD6-3858-0E80-E053-4EBD850A7E1B","beginDate":"2022-04-26","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-26","modifiedBy":"KUMMEROA","dateModified":"2022-06-15","deletedIndicator":"No"},{"value":"PEPN2121 Stratum 6B","valueDescription":"Patients with other SMARCB1 or SMARCA4 deficient tumors less than 18 years old","ValueMeaning":{"publicId":"8178425","version":"1","preferredName":"Patients with other SMARCB1 or SMARCA4 deficient tumors less than 18 years old","longName":"8178425","preferredDefinition":"PEPN2121 Stratum 6B: Patients with other SMARCB1 or SMARCA4 deficient tumors less than 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDBF26FB-9301-0637-E053-4EBD850A20FE","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDBF26FB-931A-0637-E053-4EBD850A20FE","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"PEPN2121 Stratum 6A","valueDescription":"Patients with other SMARCB1 or SMARCA4 deficient tumors greater than or equal to 18 years old","ValueMeaning":{"publicId":"8178426","version":"1","preferredName":"Patients with other SMARCB1 or SMARCA4 deficient tumors greater than or equal to 18 years old","longName":"8178426","preferredDefinition":"PEPN2121 Stratum 6A: Patients with other SMARCB1 or SMARCA4 deficient tumors greater than or equal to 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDBF26FB-9324-0637-E053-4EBD850A20FE","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDBF26FB-933D-0637-E053-4EBD850A20FE","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"PEPN2121 Stratum 5B","valueDescription":"Patients with SMARCB1 or SMARCA4 deficient tumors with Epithelioid sarcoma less than 18 years old","ValueMeaning":{"publicId":"8178427","version":"1","preferredName":"Patients with SMARCB1 or SMARCA4 deficient tumors with Epithelioid sarcoma less than 18 years old","longName":"8178427","preferredDefinition":"PEPN2121 Stratum 5B: Patients with SMARCB1 or SMARCA4 deficient tumors with Epithelioid sarcoma less than 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDBF26FB-9347-0637-E053-4EBD850A20FE","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDBF26FB-9360-0637-E053-4EBD850A20FE","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"PEPN2121 Stratum 5A","valueDescription":"Patients with SMARCB1 or SMARCA4 deficient tumors with Epithelioid sarcoma greater than or equal to 18 years old","ValueMeaning":{"publicId":"8178428","version":"1","preferredName":"Patients with SMARCB1 or SMARCA4 deficient tumors with Epithelioid sarcoma greater than or equal to 18 years old","longName":"8178428","preferredDefinition":"PEPN2121 Stratum 5A: Patients with SMARCB1 or SMARCA4 deficient tumors with Epithelioid sarcoma greater than or equal to 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDBF26FB-936A-0637-E053-4EBD850A20FE","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDBF26FB-9383-0637-E053-4EBD850A20FE","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"PEPN2121 Stratum 4B","valueDescription":"Patients with SMARCB1 or SMARCA4 deficient tumors with Poorly differentiated chordoma less than 18 years old","ValueMeaning":{"publicId":"8178429","version":"1","preferredName":"Patients with SMARCB1 or SMARCA4 deficient tumors with Poorly differentiated chordoma less than 18 years old","longName":"8178429","preferredDefinition":"PEPN2121 Stratum 4B: Patients with SMARCB1 or SMARCA4 deficient tumors with Poorly differentiated chordoma less than 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDBF26FB-938D-0637-E053-4EBD850A20FE","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDBF26FB-93A6-0637-E053-4EBD850A20FE","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"PEPN2121 Stratum 4A","valueDescription":"Patients with SMARCB1 or SMARCA4 deficient tumors with Poorly differentiated chordoma greater than or equal to 18 years old","ValueMeaning":{"publicId":"8178430","version":"1","preferredName":"Patients with SMARCB1 or SMARCA4 deficient tumors with Poorly differentiated chordoma greater than or equal to 18 years old","longName":"8178430","preferredDefinition":"PEPN2121 Stratum 4A: Patients with SMARCB1 or SMARCA4 deficient tumors with Poorly differentiated chordoma greater than or equal to 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDBF26FB-93B0-0637-E053-4EBD850A20FE","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDBF26FB-93C9-0637-E053-4EBD850A20FE","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"PEPN2121 Stratum 3B","valueDescription":"Patients with SMARCB1 or SMARCA4 deficient tumors with Atypical teratoid rhabdoid tumor (CNS) less than 18 years old","ValueMeaning":{"publicId":"8178431","version":"1","preferredName":"Patients with SMARCB1 or SMARCA4 deficient tumors with Atypical teratoid rhabdoid tumor (CNS) less than 18 years old","longName":"8178431","preferredDefinition":"PEPN2121 Stratum 3B: Patients with SMARCB1 or SMARCA4 deficient tumors with Atypical teratoid rhabdoid tumor (CNS) less than 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDBF26FB-93D3-0637-E053-4EBD850A20FE","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDBF26FB-93EC-0637-E053-4EBD850A20FE","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"PEPN2121 Stratum 3A","valueDescription":"Patients with SMARCB1 or SMARCA4 deficient tumors with Atypical teratoid rhabdoid tumor (CNS) greater than or equal to 18 years old","ValueMeaning":{"publicId":"8178432","version":"1","preferredName":"Patients with SMARCB1 or SMARCA4 deficient tumors with Atypical teratoid rhabdoid tumor (CNS) greater than or equal to 18 years old","longName":"8178432","preferredDefinition":"PEPN2121 Stratum 3A: Patients with SMARCB1 or SMARCA4 deficient tumors with Atypical teratoid rhabdoid tumor (CNS) greater than or equal to 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDBF26FB-93F6-0637-E053-4EBD850A20FE","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDBF26FB-940F-0637-E053-4EBD850A20FE","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"PEPN2121 Stratum 2B","valueDescription":"Patients with SMARCB1 or SMARCA4 deficient tumors with Malignant Rhabdoid tumor (extra-CNS) less than 18 years old","ValueMeaning":{"publicId":"8178433","version":"1","preferredName":"Patients with SMARCB1 or SMARCA4 deficient tumors with Malignant Rhabdoid tumor (extra-CNS) less than 18 years old","longName":"8178433","preferredDefinition":"PEPN2121 Stratum 2B: Patients with SMARCB1 or SMARCA4 deficient tumors with Malignant Rhabdoid tumor (extra-CNS) less than 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDBF26FB-9419-0637-E053-4EBD850A20FE","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDBF26FB-9432-0637-E053-4EBD850A20FE","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"PEPN2121 Stratum 2A","valueDescription":"Patients with SMARCB1 or SMARCA4 deficient tumors with Malignant Rhabdoid tumor (extra-CNS) greater than or equal to 18 years old","ValueMeaning":{"publicId":"8178434","version":"1","preferredName":"Patients with SMARCB1 or SMARCA4 deficient tumors with Malignant Rhabdoid tumor (extra-CNS) greater than or equal to 18 years old","longName":"8178434","preferredDefinition":"PEPN2121 Stratum 2A: Patients with SMARCB1 or SMARCA4 deficient tumors with Malignant Rhabdoid tumor (extra-CNS) greater than or equal to 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDBF26FB-943C-0637-E053-4EBD850A20FE","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDBF26FB-9455-0637-E053-4EBD850A20FE","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"PEPN2121 Stratum 1B","valueDescription":"Patients with SMARCB1 or SMARCA4 deficient tumors with Renal medullary carcinoma less than 18 years old","ValueMeaning":{"publicId":"8178435","version":"1","preferredName":"Patients with SMARCB1 or SMARCA4 deficient tumors with Renal medullary carcinoma less than 18 years old","longName":"8178435","preferredDefinition":"PEPN2121 Stratum 1B: Patients with SMARCB1 or SMARCA4 deficient tumors with Renal medullary carcinoma less than 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDBF26FB-945F-0637-E053-4EBD850A20FE","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDBF26FB-9478-0637-E053-4EBD850A20FE","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"PEPN2121 Stratum 1A","valueDescription":"Patients with SMARCB1 or SMARCA4 deficient tumors with Renal medullary carcinoma greater than or equal to 18 years old","ValueMeaning":{"publicId":"8178436","version":"1","preferredName":"Patients with SMARCB1 or SMARCA4 deficient tumors with Renal medullary carcinoma greater than or equal to 18 years old","longName":"8178436","preferredDefinition":"PEPN2121 Stratum 1A: Patients with SMARCB1 or SMARCA4 deficient tumors with Renal medullary carcinoma greater than or equal to 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDBF26FB-9482-0637-E053-4EBD850A20FE","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDBF26FB-949B-0637-E053-4EBD850A20FE","beginDate":"2022-04-28","endDate":null,"createdBy":"CARPIOJ","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"Screening","valueDescription":"Screening","ValueMeaning":{"publicId":"2570677","version":"1","preferredName":"Screening","longName":"2570677","preferredDefinition":"A systematic examination or assessment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Screening","conceptCode":"C48261","definition":"A systematic examination or assessment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E122-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"LISU","dateModified":"2022-05-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DACDE99F-2BBC-77C6-E053-4EBD850A7844","beginDate":"2022-03-22","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2022-03-22","modifiedBy":"ONEDATA","dateModified":"2022-03-22","deletedIndicator":"No"},{"value":"PEPN2121 Part A","valueDescription":null,"ValueMeaning":{"publicId":"10672161","version":"1","preferredName":"PEPN2121 Part A: Patients with SMARCB1 or SMARCA4 deficient tumors with the required histologies greater than or equal to 12 months and less than 18 years old","longName":"10672161v1.00","preferredDefinition":"PEPN2121 Part A: Patients with SMARCB1 or SMARCA4 deficient tumors with the required histologies greater than or equal to 12 months and less than 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4436806-8397-5523-E053-731AD00ACF5A","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4436806-8398-5523-E053-731AD00ACF5A","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"PEPN2121 Part B1a","valueDescription":null,"ValueMeaning":{"publicId":"10672163","version":"1","preferredName":"PEPN2121 Part B1a: Patients with SMARCB1 or SMARCA4 deficient Renal medullary carcinoma greater than or equal to 18 years old","longName":"10672163v1.00","preferredDefinition":"PEPN2121 Part B1a: Patients with SMARCB1 or SMARCA4 deficient Renal medullary carcinoma greater than or equal to 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E44386B2-1739-58BD-E053-731AD00A75EB","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E44386B2-1743-58BD-E053-731AD00A75EB","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"PEPN2121 Part B1b","valueDescription":null,"ValueMeaning":{"publicId":"10672164","version":"1","preferredName":"PEPN2121 Part B1b: Patients with SMARCB1 or SMARCA4 deficient Renal medullary carcinoma less than 18 years old","longName":"10672164v1.00","preferredDefinition":"PEPN2121 Part B1b: Patients with SMARCB1 or SMARCA4 deficient Renal medullary carcinoma less than 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E44386B2-173A-58BD-E053-731AD00A75EB","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E44386B2-1744-58BD-E053-731AD00A75EB","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"PEPN2121 Part B2a","valueDescription":null,"ValueMeaning":{"publicId":"10672165","version":"1","preferredName":"PEPN2121 Part B2a: Patients with SMARCB1 or SMARCA4 deficient Malignant Rhabdoid tumor (extra-CNS) greater than or equal to 18 years old","longName":"10672165v1.00","preferredDefinition":"PEPN2121 Part B2a: Patients with SMARCB1 or SMARCA4 deficient Malignant Rhabdoid tumor (extra-CNS) greater than or equal to 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E44386B2-173B-58BD-E053-731AD00A75EB","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E44386B2-1745-58BD-E053-731AD00A75EB","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"PEPN2121 Part B2b","valueDescription":null,"ValueMeaning":{"publicId":"10672166","version":"1","preferredName":"PEPN2121 Part B2b: Patients with SMARCB1 or SMARCA4 deficient Malignant Rhabdoid tumor (extra-CNS) less than 18 years old","longName":"10672166v1.00","preferredDefinition":"PEPN2121 Part B2b: Patients with SMARCB1 or SMARCA4 deficient Malignant Rhabdoid tumor (extra-CNS) less than 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E44386B2-173C-58BD-E053-731AD00A75EB","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E44386B2-1746-58BD-E053-731AD00A75EB","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"PEPN2121 Part B3b","valueDescription":null,"ValueMeaning":{"publicId":"10672168","version":"1","preferredName":"PEPN2121 Part B3b: Patients with SMARCB1 or SMARCA4 deficient Atypical teratoid rhabdoid tumor (CNS) less than 18 years old","longName":"10672168v1.00","preferredDefinition":"PEPN2121 Part B3b: Patients with SMARCB1 or SMARCA4 deficient Atypical teratoid rhabdoid tumor (CNS) less than 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E44386B2-173E-58BD-E053-731AD00A75EB","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E44386B2-1747-58BD-E053-731AD00A75EB","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"PEPN2121 Part B4a","valueDescription":null,"ValueMeaning":{"publicId":"10672169","version":"1","preferredName":"PEPN2121 Part B4a: Patients with SMARCB1 or SMARCA4 deficient Poorly differentiated chordoma greater than or equal to 18 years old","longName":"10672169v1.00","preferredDefinition":"PEPN2121 Part B4a: Patients with SMARCB1 or SMARCA4 deficient Poorly differentiated chordoma greater than or equal to 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E44386B2-173F-58BD-E053-731AD00A75EB","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E44386B2-1748-58BD-E053-731AD00A75EB","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"PEPN2121 Part B4b","valueDescription":null,"ValueMeaning":{"publicId":"10672170","version":"1","preferredName":"PEPN2121 Part B4b: Patients with SMARCB1 or SMARCA4 deficient Poorly differentiated chordoma less than 18 years old","longName":"10672170v1.00","preferredDefinition":"PEPN2121 Part B4b: Patients with SMARCB1 or SMARCA4 deficient Poorly differentiated chordoma less than 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E44386B2-1740-58BD-E053-731AD00A75EB","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E44386B2-1749-58BD-E053-731AD00A75EB","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"PEPN2121 Part B5a","valueDescription":null,"ValueMeaning":{"publicId":"10672171","version":"1","preferredName":"PEPN2121 Part B5a: Patients with SMARCB1 or SMARCA4 deficient Epithelioid sarcoma greater than or equal to 18 years old","longName":"10672171v1.00","preferredDefinition":"PEPN2121 Part B5a: Patients with SMARCB1 or SMARCA4 deficient Epithelioid sarcoma greater than or equal to 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E44386B2-1741-58BD-E053-731AD00A75EB","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E44386B2-174A-58BD-E053-731AD00A75EB","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"PEPN2121 Part B5b","valueDescription":null,"ValueMeaning":{"publicId":"10672172","version":"1","preferredName":"PEPN2121 Part B5b: Patients with SMARCB1 or SMARCA4 deficient Epithelioid sarcoma less than 18 years old","longName":"10672172v1.00","preferredDefinition":"PEPN2121 Part B5b: Patients with SMARCB1 or SMARCA4 deficient Epithelioid sarcoma less than 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E44386B2-1742-58BD-E053-731AD00A75EB","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E44386B2-174B-58BD-E053-731AD00A75EB","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"PEPN2121 Part B3a","valueDescription":null,"ValueMeaning":{"publicId":"10672167","version":"1","preferredName":"PEPN2121 Part B3a: Patients with SMARCB1 or SMARCA4 deficient Atypical teratoid rhabdoid tumor (CNS) greater than or equal to 18 years old","longName":"10672167v1.00","preferredDefinition":"PEPN2121 Part B3a: Patients with SMARCB1 or SMARCA4 deficient Atypical teratoid rhabdoid tumor (CNS) greater than or equal to 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E44386B2-173D-58BD-E053-731AD00A75EB","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E44386B2-174C-58BD-E053-731AD00A75EB","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"PEPN2121 Part B6a","valueDescription":null,"ValueMeaning":{"publicId":"10672173","version":"1","preferredName":"PEPN2121 Part B6a: Patients with other SMARCB1 or SMARCA4 deficient tumors greater than or equal to 18 years old","longName":"10672173v1.00","preferredDefinition":"PEPN2121 Part B6a: Patients with other SMARCB1 or SMARCA4 deficient tumors greater than or equal to 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E443932F-275A-5A1A-E053-731AD00A7FF1","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E443932F-275C-5A1A-E053-731AD00A7FF1","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"PEPN2121 Part B6b","valueDescription":null,"ValueMeaning":{"publicId":"10672174","version":"1","preferredName":"PEPN2121 Part B6b: Patients with other SMARCB1 or SMARCA4 deficient tumors less than 18 years old","longName":"10672174v1.00","preferredDefinition":"PEPN2121 Part B6b: Patients with other SMARCB1 or SMARCA4 deficient tumors less than 18 years old","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E443932F-275B-5A1A-E053-731AD00A7FF1","latestVersionIndicator":"Yes","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E443932F-275D-5A1A-E053-731AD00A7FF1","beginDate":"2022-07-20","endDate":null,"createdBy":"LISU","dateCreated":"2022-07-20","modifiedBy":"LISU","dateModified":"2022-07-20","deletedIndicator":"No"},{"value":"PEPN22P1 Stratum 1","valueDescription":null,"ValueMeaning":{"publicId":"11413584","version":"1","preferredName":"PEPN22P1 Stratum 1: Patients with newly diagnosed and relapsed cancer diagnosis that are being treated with vinCRIStine at the 1.5 mg/m^2 dose level. Age 0 to 6 months.","longName":"11413584v1.00","preferredDefinition":"PEPN22P1 Stratum 1: Patients with newly diagnosed and relapsed cancer diagnosis that are being treated with vinCRIStine at the 1.5 mg/m^2 dose level. Age 0 to 6 months.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAB40C95-91DC-20CE-E053-731AD00A8E86","latestVersionIndicator":"Yes","beginDate":"2022-10-10","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-10-10","modifiedBy":"MMADDINENI","dateModified":"2022-10-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAB40C95-91E0-20CE-E053-731AD00A8E86","beginDate":"2022-10-10","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-10-10","modifiedBy":"GDEEN","dateModified":"2022-10-17","deletedIndicator":"No"},{"value":"PEPN22P1 Stratum 2","valueDescription":null,"ValueMeaning":{"publicId":"11413585","version":"1","preferredName":"PEPN22P1 Stratum 2: Patients with newly diagnosed and relapsed cancer diagnosis that are being treated with vinCRIStine at the 1.5 mg/m^2 dose level. Age 6 months and 1 day to 12 months.","longName":"11413585v1.00","preferredDefinition":"PEPN22P1 Stratum 2: Patients with newly diagnosed and relapsed cancer diagnosis that are being treated with vinCRIStine at the 1.5 mg/m^2 dose level. Age 6 months and 1 day to 12 months.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAB40C95-91DD-20CE-E053-731AD00A8E86","latestVersionIndicator":"Yes","beginDate":"2022-10-10","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-10-10","modifiedBy":"MMADDINENI","dateModified":"2022-10-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAB40C95-91E1-20CE-E053-731AD00A8E86","beginDate":"2022-10-10","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-10-10","modifiedBy":"GDEEN","dateModified":"2022-10-17","deletedIndicator":"No"},{"value":"PEPN22P1 Stratum 3","valueDescription":null,"ValueMeaning":{"publicId":"11413586","version":"1","preferredName":"PEPN22P1 Stratum 3: Patients with newly diagnosed and relapsed cancer diagnosis that are being treated with vinCRIStine at the 1.5 mg/m^2 dose level. Age 12 months and 1 day to 36 months.","longName":"11413586v1.00","preferredDefinition":"PEPN22P1 Stratum 3: Patients with newly diagnosed and relapsed cancer diagnosis that are being treated with vinCRIStine at the 1.5 mg/m^2 dose level. Age 12 months and 1 day to 36 months.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAB40C95-91DE-20CE-E053-731AD00A8E86","latestVersionIndicator":"Yes","beginDate":"2022-10-10","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-10-10","modifiedBy":"MMADDINENI","dateModified":"2022-10-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAB40C95-91E2-20CE-E053-731AD00A8E86","beginDate":"2022-10-10","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-10-10","modifiedBy":"MMADDINENI","dateModified":"2022-10-10","deletedIndicator":"No"},{"value":"PEPN22P1 Stratum 4","valueDescription":null,"ValueMeaning":{"publicId":"11413587","version":"1","preferredName":"PEPN22P1 Stratum 4: Patients with newly diagnosed and relapsed cancer diagnosis that are being treated with vinCRIStine at the 1.5 mg/m^2 dose level. Age 36 months and 1 day to 12 years.","longName":"11413587v1.00","preferredDefinition":"PEPN22P1 Stratum 4: Patients with newly diagnosed and relapsed cancer diagnosis that are being treated with vinCRIStine at the 1.5 mg/m^2 dose level. Age 36 months and 1 day to 12 years.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAB40C95-91DF-20CE-E053-731AD00A8E86","latestVersionIndicator":"Yes","beginDate":"2022-10-10","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-10-10","modifiedBy":"MMADDINENI","dateModified":"2022-10-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EAB40C95-91E3-20CE-E053-731AD00A8E86","beginDate":"2022-10-10","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-10-10","modifiedBy":"MMADDINENI","dateModified":"2022-10-10","deletedIndicator":"No"},{"value":"AOST2032 Stratum 1","valueDescription":null,"ValueMeaning":{"publicId":"11167517","version":"1","preferredName":"Stratum 1: Feasibility Phase Patients","longName":"11167517v1.00","preferredDefinition":"Stratum 1: Feasibility Phase Patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E78F866C-5C48-4965-E053-731AD00A8FFA","latestVersionIndicator":"Yes","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EEDE8628-C10E-35E1-E053-731AD00AD8B0","beginDate":"2022-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-12-02","modifiedBy":"KUMMEROA","dateModified":"2022-12-02","deletedIndicator":"No"},{"value":"AOST2032 Stratum 2","valueDescription":null,"ValueMeaning":{"publicId":"11167518","version":"1","preferredName":"Stratum 2: Standard Risk Patients","longName":"11167518v1.00","preferredDefinition":"Stratum 2: Standard Risk Patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E78F866C-5C49-4965-E053-731AD00A8FFA","latestVersionIndicator":"Yes","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EEDE8628-C10F-35E1-E053-731AD00AD8B0","beginDate":"2022-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-12-02","modifiedBy":"KUMMEROA","dateModified":"2022-12-02","deletedIndicator":"No"},{"value":"AOST2032 Stratum 3","valueDescription":null,"ValueMeaning":{"publicId":"11167519","version":"1","preferredName":"Stratum 3: High Risk Patients","longName":"11167519v1.00","preferredDefinition":"Stratum 3: High Risk Patients","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E78F866C-5C4A-4965-E053-731AD00A8FFA","latestVersionIndicator":"Yes","beginDate":"2022-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-31","modifiedBy":"KUMMEROA","dateModified":"2022-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EEDE8628-C110-35E1-E053-731AD00AD8B0","beginDate":"2022-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-12-02","modifiedBy":"KUMMEROA","dateModified":"2022-12-02","deletedIndicator":"No"},{"value":"EAY191-C1 Cohort 1","valueDescription":null,"ValueMeaning":{"publicId":"13261115","version":"1","preferredName":"EAY191-C1.C1: People w/ LGG w/ BRAF SNVs, BRAF fusions, or NF1 deletions progressive on either a MEK inhibitor or BRAF V600E (Type I) inhibitor monotx","longName":"13261115v1.00","preferredDefinition":"EAY191-C1.C1: People w/ LGG w/ BRAF SNVs, BRAF fusions, or NF1 deletions progressive on either a MEK inhibitor or BRAF V600E (Type I) inhibitor monotx","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7F87038-9955-1BC4-E053-731AD00AA775","latestVersionIndicator":"Yes","beginDate":"2023-03-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-28","modifiedBy":"KUMMEROA","dateModified":"2023-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7F87038-9959-1BC4-E053-731AD00AA775","beginDate":"2023-03-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-28","deletedIndicator":"No"},{"value":"EAY191-C1 Cohort 2","valueDescription":null,"ValueMeaning":{"publicId":"13261116","version":"1","preferredName":"EAY191-C1.C2: People w/ solid tumors w/ alterations in BRAF or RAF1 (BRAF V600E altered tumors must have progressed on BRAF V600E (Type I) inhibitor)","longName":"13261116v1.00","preferredDefinition":"EAY191-C1.C2: People w/ solid tumors w/ alterations in BRAF or RAF1 (BRAF V600E altered tumors must have progressed on BRAF V600E (Type I) inhibitor)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7F87038-9956-1BC4-E053-731AD00AA775","latestVersionIndicator":"Yes","beginDate":"2023-03-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-28","modifiedBy":"KUMMEROA","dateModified":"2023-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7F87038-995A-1BC4-E053-731AD00AA775","beginDate":"2023-03-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-28","deletedIndicator":"No"},{"value":"EAY191-C1 Cohort 3","valueDescription":null,"ValueMeaning":{"publicId":"13261117","version":"1","preferredName":"EAY191-C1.C3: People with solid tumors and alternations in HRAS, KRAS, or NRAS","longName":"13261117v1.00","preferredDefinition":"EAY191-C1.C3: People with solid tumors and alternations in HRAS, KRAS, or NRAS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7F87038-9957-1BC4-E053-731AD00AA775","latestVersionIndicator":"Yes","beginDate":"2023-03-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-28","modifiedBy":"KUMMEROA","dateModified":"2023-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7F87038-995B-1BC4-E053-731AD00AA775","beginDate":"2023-03-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-28","deletedIndicator":"No"},{"value":"EAY191-C1 Cohort 4","valueDescription":null,"ValueMeaning":{"publicId":"13261118","version":"1","preferredName":"EAY191-C1.C4: People with solid tumors with deleterious alterations in NF1","longName":"13261118v1.00","preferredDefinition":"EAY191-C1.C4: People with solid tumors with deleterious alterations in NF1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7F87038-9958-1BC4-E053-731AD00AA775","latestVersionIndicator":"Yes","beginDate":"2023-03-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-28","modifiedBy":"KUMMEROA","dateModified":"2023-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7F87038-995C-1BC4-E053-731AD00AA775","beginDate":"2023-03-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-28","deletedIndicator":"No"},{"value":"SG1: Dose Escalation","valueDescription":null,"ValueMeaning":{"publicId":"8119909","version":"1","preferredName":"SG1: Dose Escalation","longName":"8119909","preferredDefinition":"SG1: Dose Escalation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB0A58B4-1D98-4C16-E053-4EBD850A3737","latestVersionIndicator":"Yes","beginDate":"2022-03-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-03-25","modifiedBy":"KUMMEROA","dateModified":"2022-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F0B785-E3D9-2E6D-E063-731AD00A9D9B","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","deletedIndicator":"No"},{"value":"SG2: Dose Escalation","valueDescription":null,"ValueMeaning":{"publicId":"14240916","version":"1","preferredName":"SG2: Dose Escalation","longName":"14240916v1.00","preferredDefinition":"SG2: Dose Escalation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01F0B785-E3D8-2E6D-E063-731AD00A9D9B","latestVersionIndicator":"Yes","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F0B785-E3DA-2E6D-E063-731AD00A9D9B","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","deletedIndicator":"No"},{"value":"PED-CITN-02 Stratum 1","valueDescription":null,"ValueMeaning":{"publicId":"14240917","version":"1","preferredName":"Patients with recurrent or refractory histologically confirmed NBL or osteosarcoma who are less than or equal to 40 years of age","longName":"14240917v1.00","preferredDefinition":"Patients with recurrent or refractory histologically confirmed NBL or osteosarcoma who are less than or equal to 40 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01F0C307-72F1-3056-E063-731AD00A67DF","latestVersionIndicator":"Yes","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F0C307-72F4-3056-E063-731AD00A67DF","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","deletedIndicator":"No"},{"value":"PED-CITN-02 Stratum 2","valueDescription":null,"ValueMeaning":{"publicId":"14240918","version":"1","preferredName":"Patients with progressive, recurrent, or refractory osteosarcoma who are less than or equal to 40 years of age","longName":"14240918v1.00","preferredDefinition":"Patients with progressive, recurrent, or refractory osteosarcoma who are less than or equal to 40 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01F0C307-72F2-3056-E063-731AD00A67DF","latestVersionIndicator":"Yes","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F0C307-72F5-3056-E063-731AD00A67DF","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","deletedIndicator":"No"},{"value":"PED-CITN-02 Stratum 3","valueDescription":null,"ValueMeaning":{"publicId":"14240919","version":"1","preferredName":"Patients with progressive, recurrent, or refractory neuroblastoma who are less than or equal to 40 years of age","longName":"14240919v1.00","preferredDefinition":"Patients with progressive, recurrent, or refractory neuroblastoma who are less than or equal to 40 years of age","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01F0C307-72F3-3056-E063-731AD00A67DF","latestVersionIndicator":"Yes","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F0C307-72F6-3056-E063-731AD00A67DF","beginDate":"2023-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-08-02","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","deletedIndicator":"No"},{"value":"SG2: Dose Expansion","valueDescription":null,"ValueMeaning":{"publicId":"7452983","version":"1","preferredName":"SG2: Dose expansion","longName":"7452983v1.00","preferredDefinition":"SG2: Dose expansion","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0F1D50B-922F-3F15-E053-4EBD850A7105","latestVersionIndicator":"Yes","beginDate":"2020-10-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2020-10-05","modifiedBy":"GDEEN","dateModified":"2023-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"02ADCD8F-42CD-6970-E063-731AD00A5BA7","beginDate":"2023-08-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-11","modifiedBy":"GDEEN","dateModified":"2023-08-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008528","version":"1","preferredName":"Protocol Administration","preferredDefinition":"the management of a research protocol and its case report forms.","longName":"PROT_ADM","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECAD41-A932-34B1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7430768","version":"1","preferredName":"Children's Oncology Group Stratification Factors Text","preferredDefinition":"An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.:Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.:The words of something written.","longName":"C39353:C16153:C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Children's Oncology Group","conceptCode":"C39353","definition":"An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stratification Factors","conceptCode":"C16153","definition":"Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFEE125F-1A09-66AF-E053-4EBD850A0C8B","latestVersionIndicator":"Yes","beginDate":"2020-09-22","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-22","modifiedBy":"ONEDATA","dateModified":"2020-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF4A16CC-5B58-17B6-E053-4EBD850A2842","latestVersionIndicator":"Yes","beginDate":"2020-09-14","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"GDEEN","dateModified":"2023-08-11","changeDescription":null,"administrativeNotes":"2023.8.2 PVs added per ticket request CADSR0002682. ak 2023.6.28 Updated PVs due to change in study. ak 2023.3.28 PVs added per ticket request CADSR0002221. ak 2022.12.2 PVs added for ticket request CADSR0001756. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"ACNS1931 Stratum:","url":null,"context":"COG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"PEPN1924 Stratum:","url":null,"context":"COG"},{"name":"Stratum:","type":"Preferred Question Text","description":"Stratum:","url":null,"context":"COG"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"PEPN2111 Stratum:","url":null,"context":"COG"},{"name":"COG CRF Text 5","type":"Alternate Question Text","description":"PEPN2011 Stratum:","url":null,"context":"COG"},{"name":"COG CRF Text 6","type":"Alternate Question Text","description":"PEPN2112 Stratum:","url":null,"context":"COG"},{"name":"COG CRF Text 7","type":"Alternate Question Text","description":"PEPN2113 Stratum:","url":null,"context":"COG"},{"name":"COG CRF Text 8","type":"Alternate Question Text","description":"PEPN2121 Stratum:","url":null,"context":"COG"},{"name":"COG CRF Text 9","type":"Alternate Question Text","description":"ANHL2121 Stratum:","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"ASCT2121 Stratum:","url":null,"context":"COG"},{"name":"COG CRF TEXT 10","type":"Alternate Question Text","description":"PEPN22P1 Stratum:","url":null,"context":"COG"},{"name":"COG CRF Text 11","type":"Alternate Question Text","description":"AOST2032 Stratum:","url":null,"context":"COG"},{"name":"COG CRF Text 12","type":"Alternate Question Text","description":"EAY191-C1 Stratum:","url":null,"context":"COG"},{"name":"COG CRF Text 13","type":"Alternate Question Text","description":"PEP-CITN-02 Stratum:","url":null,"context":"COG"},{"name":"COG CRF Text 14","type":"Alternate Question Text","description":"ARAR2221 Stratum:","url":null,"context":"COG"},{"name":"COG CRF Text 15","type":"Alternate Question Text","description":"ANBL2131 Stratum:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF4B325B-15E2-3964-E053-4EBD850AB0F3","latestVersionIndicator":"Yes","beginDate":"2020-09-14","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-09-14","modifiedBy":"KUMMEROA","dateModified":"2024-01-04","changeDescription":null,"administrativeNotes":"2024.1.4 AT added per ticket request CADSR-TASK0003337. ak 2023.11.29 AQT/Alt SN added per ticket request Ticket Request CADSR0003032. ak 2023.8.2 AQT added per ticket request CADSR0002682. ak 2023.3.28 AQT added per ticket request CADSR0002221. ak 2022.10.4 AQT added for ticket request CADSR0001571. ak 2022.12.2 AQT added for ticket request CADSR0001756. ak","unresolvedIssues":null,"deletedIndicator":"No"}}